钠-葡萄糖耦联转运体2抑制剂治疗心力衰竭的研究进展

Research progress on sodium-glucose linked transporter 2 inhibitors in the treatment of heart failure

心力衰竭(heart failure,HF)患者死亡风险较高,而糖尿病(diabetes mellitus,DM)是HF的重要危险因素。钠-葡萄糖耦联转运体2(sodium-glucose linked transporter 2,SGLT2)抑制剂作为近年来的一种新型抗高血糖药,已被证实可预防心血管事件,改善射血分数下降的HF(heart failure with reduced ejection fraction,HFrEF)患者预后,降低HF住院风险及心血管死亡风险,且这种获益在伴或不伴DM患者中是一致的。现就SGLT2抑制剂对心血管结局,尤其是影响HF的相关既往文献进行综述,旨在为临床用药提供参考。

Patients with heart failure(HF)have a higher risk of death,and diabetes mellitus(DM)is an important risk factor for HF.Sodium-glucose linked transporter 2(SGLT2)inhibitor,as a new anti-hyperglycemia drug in recent years,has been proved to prevent cardiovascular events and improve the prognosis of patients with HF with reduced ejection fraction(HFrEF),and reduce the risk of HF hospitalization and cardiovascular death.This benefit is consistent in patients with or without DM.This article reviewed the previous literature on the effects of SGLT2 inhibitors on cardiovascular outcomes,especially on HF,in order to provide references for clinical medication.